Metformin Lich Winthrop (Metformin Hydrochloride)

Metformin primarily inhibits mitochondrial complex I, which lowers hepatic gluconeogenesis. It also activates AMP‑activated protein kinase (AMPK), leading to increased glucose uptake in muscle and fat cells and improved peripheral insulin sensitivity, without directly stimulating insulin secretion.

The dosage of Metformin Lich Winthrop is individualized by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of metformin in pregnancy or while breastfeeding is not fully established. Healthcare providers weigh potential benefits against risks for each patient. Women who are pregnant, planning pregnancy, or nursing should discuss use with their physician before starting therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin belongs to the biguanide class, differing from sulfonylureas, DPP‑4 inhibitors, or SGLT2 inhibitors. Unlike insulin‑secretagogues, metformin does not cause hypoglycemia when used alone and has a favorable effect on weight. It is often first‑line therapy because of its efficacy, safety profile, and low cost.

Metformin Lich Winthrop tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and not crush or chew the tablets unless instructed.

The most serious adverse effect is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or conditions causing hypoxia. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving iodinated contrast studies without adequate hydration. Clinicians should assess each patient’s medical history before prescribing.